Back
Full-text
Journal article

Biology and therapeutic targeting of tumour-associated macrophages.

  • Beltraminelli T Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
  • De Palma M Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
  • 2020-02-23
Published in:
  • The Journal of pathology. - 2020
clinical trial
macrophage
monocyte
therapeutic targeting
tumour microenvironment
Humans
Immune System
Macrophages
Neoplasms
Neovascularization, Pathologic
Tumor Microenvironment
United Kingdom
English Macrophages sustain tumour progression by facilitating angiogenesis, promoting immunosuppression, and enhancing cancer cell invasion and metastasis. They also modulate tumour response to anti-cancer therapy in pre-clinical models. This knowledge has motivated the development of agents that target tumour-associated macrophages (TAMs), some of which have been investigated in early clinical trials. Here, we provide a comprehensive overview of the biology and therapeutic targeting of TAMs, highlighting opportunities, setbacks, and new challenges that have emerged after a decade of intense translational and clinical research into these multifaceted immune cells. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/20692
Statistics
Document views: 51 File downloads:
  • Full-text: 0